Avantor Inc

Avantor reported second-quarter 2026 results showing its Revival program is improving execution, with VWR Distribution & Services returning to 1.7% organic growth ahead of expectations and management raising its full-year outlook. Bioscience & Medtech Products organic revenue fell 5.6% year over year, though the segment posted double-digit order growth and a 1.1 times book-to-bill ratio, with management expecting organic growth to return in the second half of 2026. Gross margin contracted about 120 basis points to 31.7% and adjusted operating margin fell 170 basis points to 13.3%, pressured by lower volumes, unfavorable mix, inflation and higher freight costs. Avantor raised its 2026 organic revenue growth outlook to negative 0.5% to positive 0.5% and lifted adjusted earnings per share guidance to 80-83 cents, while ending the quarter with about $307 million in cash and total debt of roughly $3.7 billion, having repaid $112.1 million of debt during the quarter. The stock carries a Zacks Rank #2 (Buy), but its Value Score of C, Growth Score of D, Momentum Score of F and VGM Score of D do not reinforce the Rank, supporting a selective stance while the recovery develops.

Avantor raised its full-year 2026 sales and earnings guidance after second-quarter adjusted results beat analyst expectations, driven by earlier-than-expected organic growth in its VWR Distribution & Services segment. The company reported sales of US$1,692.3 million, slightly above the prior-year period, while GAAP net income and earnings per share from continuing operations declined. The upgraded outlook addresses concerns about flat or negative organic growth and underutilized capacity, though compressed margins and elevated leverage remain key risks. Management’s long-term projections target US$6.9 billion in revenue and US$566.4 million in earnings by 2029.

Several biotech stocks posted sharp gains on Wednesday, led by SciSparc after its subsidiary completed internal validation of a quantum sampling platform for clinical trial data. SciSparc closed at $9.09, up 70.54%, following the announcement that NeuroThera Labs successfully validated the platform being advanced by CliniQuantum, in which NeuroThera holds a 54.01% ownership interest. Avantor rose 15.78% to $14.38 after reporting second-quarter net sales of $1.69 billion and raising its full-year adjusted EPS guidance to $0.80 to $0.83 from $0.77 to $0.83. NeoGenomics gained 13.96% to $15.27 after second-quarter consolidated revenue increased 11% to $202 million and the company lifted its full-year revenue outlook to $802 million to $806 million from $797 million to $803 million. Alvotech climbed 13.87% to $3.53 after the FDA classified the inspection of its Reykjavik manufacturing facility as Voluntary Action Indicated, a step forward for its biosimilar applications. Sanara MedTech surged 13.55% to $30.25 after agreeing to be acquired by MiMedx Group in a cash-and-stock deal valued at $35 per share, or about $350 million in total enterprise value. LB Pharmaceuticals advanced 11.62% to $39.00 after securing a $150 million private placement and accelerating the timeline for topline results from its Phase 3 schizophrenia trial to the first half of 2027.

Avantor, through its NuSil brand, has expanded its collaboration with the Population Council to support development of a three-month dapivirine vaginal ring for HIV prevention. The partnership deepens Avantor's role in a program already under European Medicines Agency review, with the company supplying high-purity silicones for both the existing one-month ring and the new three-month version. The three-month profile is intended to improve adherence compared with more frequent dosing, particularly for women in regions with higher HIV prevalence. While the project highlights Avantor's position in specialized medical materials, it does not directly address concerns around bioprocessing demand softness and margin pressures. Investors may watch for regulatory milestones and any disclosures on commercial supply agreements that could clarify the project's revenue impact.

Waters Corporation delivered the strongest first-quarter performance among the ten research tools and consumables stocks tracked, with revenues of $1.27 billion, up 91.5% year on year and beating analysts' estimates by 4.5%. The company also posted the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Avantor reported revenues of $1.58 billion, flat year on year but exceeding expectations by 2.7%, while Revvity's revenues of $686.9 million, up 9.3% year on year, fell short of estimates by 2.6% and came with full-year guidance that missed expectations. Sotera Health Company posted revenues of $280 million, up 10% year on year and topping estimates by 3.6%, and Bio-Techne reported revenues of $311.4 million, down 1.5% year on year and missing estimates by 1.6%. Overall, the group's revenues beat consensus estimates by 1.3%, and next-quarter revenue guidance was 2% above expectations, with share prices up 22.5% on average since the latest earnings results.

Avantor, Inc. has a history of beating earnings estimates and shows potential for another beat in its next quarterly report. The company posted an average earnings surprise of 5.51% over the past two quarters, with a 6.25% beat in the most recent quarter and a 4.76% beat in the previous one. Avantor currently has a positive Earnings ESP of +1.30% and a Zacks Rank of 3, a combination that historically produces a positive surprise nearly 70% of the time. Its next earnings report is expected on July 29, 2026.

Longleaf Partners Fund highlighted life-sciences company Avantor as a contributor in the second quarter of 2026, citing stabilization and progress under new CEO Emmanuel Ligner. The fund noted that book-to-bill rose above one, a solid leading indicator, and that the new management team is advancing operational initiatives including a redesigned VWR website and improved ship-to-order patterns in the Bioprocessing business. Ligner is guiding to revenue growth and strong free cash flow generation in the second half of 2026. The fund also pointed to Merck KGaA's recent purchase of Bio-Techne at a solid teens EBITDA multiple as evidence of ongoing attractiveness in the space despite slower near-term revenue growth.

Avantor is positioned for growth driven by strategic deals and its cost-transformation program, though softness in the VWR Distribution & Services segment remains a concern. The company secured roughly $100 million in new business wins across two top-15 global pharma customers that will begin phasing in from 2026, and executed a five-year extension with BIO Business Solutions expanding access to over 10,000 life sciences customers. First-quarter 2026 results exceeded management's expectations, with the company reaffirming full-year 2026 guidance for organic revenue growth of negative 2.5% to negative 0.5% and adjusted earnings per share in the range of 77 cents to 83 cents. The VWR Distribution & Services segment generated $1.15 billion in revenues in the first quarter, declining 5% organically year over year, though management believes the segment reached a trough in that period. Avantor expects positive organic revenue growth in the second half of 2026, supported by improving demand trends and a book-to-bill ratio above 1.1x in the Biopharma Production segment.

Shares of life sciences company Avantor jumped 3.2% in morning trading after Barclays raised its price target and the company formally concluded its CFO transition on June 24, removing a governance concern. The rally was also fueled by growing confidence in the company's Revival turnaround plan and signs that its bioscience and medtech operations are stabilizing, attracting more institutional buyers. Sentiment in the broader life sciences sector was positive after Merck KGaA agreed to acquire Bio-Techne for approximately $11.3 billion. The stock was trading at $10.10, up 4.3% from the previous close.